Fondaparinux in Pulmonary Embolism [3]

New England Journal of Medicine

Volumn 350, Issue 6, 2004, Pages 619-

  Wertz, James ^a  

^a ST ELIZABETH HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; HEPARIN;

CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; LETTER; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STANDARD; VALIDATION PROCESS;

FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; PARTIAL THROMBOPLASTIN TIME; POLYSACCHARIDES; PULMONARY EMBOLISM;

EID: 0742322738     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200402053500620     Document Type: Letter

References (4)

1. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702.
2. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003;138:720-3.
3. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:Suppl:176S-193S.
4. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.